Amneal Files Xolair Biosimilar In US ‘Earlier Than Expected’

Anticipates Potential First-Wave Entry Into The $4bn+ US Market

 
• By Dave Wallace
  
Amneal has submitted its omalizumab filing to the FDA ahead of time (Shutterstock)

More from Biosimilars

More from Products